Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443924 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL9155520 | 0.91 | EGFR (0.55) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL9160532 | 0.90 | KMT2A (0.52) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL8366302 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL31376496 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL29063256 | 0.82 | EGFR (0.56) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL9766051 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL8707975 | 0.81 | HPGD (0.51) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL30175797 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL30430848 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KMT2AKDM4EMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-114588156-A | Ophthalmic preparation and application thereof in treating presbyopia | 温州医科大学附属眼视光医院 | 2022-06-07 | — | — | CN | disclosed |
| US-11318095-B2 | Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same | TEIKA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20210137836-A1 | MICELLE FOR SOLUBILIZING A SPARINGLY WATER-SOLUBLE INGREDIENT AND SOLUTION COMPRISING THE SAME | TEIKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-13 | — | — | US | disclosed |
| CN-1934086-B | Amine salt of carbostyril derivative | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| US-7879877-B2 | orally administering 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid, for the prophylaxis and/or treatment of xerostomia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20070112026-A1 | Carbostyril derivatives for accelerating salivation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1706383-A1 | AMINE SALT OF CARBOSTYRIL DERIVATIVE | Otsuka Pharmaceutical Company, Limited (JP) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005070892-A1 | AMINE SALT OF CARBOSTYRIL DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | WO | disclosed |
| CN-1073418-C | Interleukin-8 production inhibitor | 大塚制药株式会社 | 2001-10-24 | — | — | CN | disclosed |
| US-4138490-A | Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137836-A1 | MICELLE FOR SOLUBILIZING A SPARINGLY WATER-SOLUBLE INGREDIENT AND SOLUTION COMPRISING THE SAME | CETP, LIPA, MUC1 | ALDH1A1 4658/4885KMT2A 3708/4885KDM4E 4309/4885 |
| US-11318095-B2 | Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same | CETP, LIPA, MUC1 | ALDH1A1 4658/4885KMT2A 3708/4885KDM4E 4309/4885 |
| US-20070112026-A1 | Carbostyril derivatives for accelerating salivation | TAS2R40, TAS2R41, TAS2R42 | ALDH1A1 3460/4885KMT2A 3304/4885KDM4E 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.